蒙特卡洛模拟厄洛替尼漏服及补服方案评价

doi:10.12092/j.issn.1009-2501.2020.05.009

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (5): 540-545.doi: 10.12092/j.issn.1009-2501.2020.05.009

蒙特卡洛模拟厄洛替尼漏服及补服方案评价

许高奇^1,2, 张轶雯³, 郑小卫^1,2,刘宇佳^1,2,李莉⁴,黄萍³

1中国科学院大学附属肿瘤医院(浙江省肿瘤医院),杭州 310022,浙江;
2中国科学院肿瘤与基础医学研究所,杭州 310022,浙江;
3浙江省人民医院药剂科,杭州 310014,浙江;
4浙江省淳安县第一人民医院药剂科,杭州 311700,浙江

发布日期:2020-07-06
通讯作者: 黄萍,女,主任药师,研究方向:医院药学。E-mail: huangping1841@zjcc.org.cn
作者简介:许高奇,男,药师,研究方向:定量药理学。E-mail: xugq@zjcc.org.cn
基金资助:
浙江省医药卫生科技计划项目(2017RC001,2018KY148)

Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation

XU Gaoqi^1,2, ZHANG Yiwen³, ZHENG Xiaowei^1,2, LIU Yujia^1,2, LI Li⁴, HUANG Ping³

1 Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, Zhejiang, China;
2 Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang, China;
3 Department of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang, China;
4 Department of Pharmacy, the First People's Hospital of Chun-an, Hangzhou 311700, Zhejiang, China

Published:2020-07-06

摘要/Abstract

摘要： 目的:根据厄洛替尼群体药动学(PPK)模型,应用蒙特卡洛模拟(MCS)评价肿瘤患者厄洛替尼漏服及补服方案。方法:根据厄洛替尼PPK模型,以口服150 mg qd为给药方案,应用非线性混合效应动力学模型(NONMEM)软件对患者漏服及不同时间段补服方案(6 h,12 h,18 h,24 h双倍剂量补服)进行10 000次MCS,计算漏服及补服方案下个体治疗窗(ITW)外人群比例和ITW外持续时间(>5%人群),评估各场景下补服方案的合理性。结果:患者漏服厄洛替尼时,血药浓度持续下降至下次用药时间,且影响次日的血药浓度,ITW以下持续时间分别为25.1 h和6.6 h;随着补服时间的延长,ITW以下人群比例从6.82%增加到14.55%,持续时间从5.9 h增加到23.6 h;ITW以上人群比例从5.99%增加到10.74%,持续时间从3.7 h增加到9.7 h。结论:根据MCS结果,患者应提高厄洛替尼用药依从性,避免漏服。一旦出现漏服,可考虑尽快补服,但不建议接近下次给药时间时进行补服或加倍剂量补服,以免增加药物不良反应。

关键词: 厄洛替尼, 用药依从性, 群体药动学, 蒙特卡洛模拟

Abstract: AIM: To evaluate the missed and remedial dosage regimens in cancer patients using erlotinib population pharmacokinetics (PPK) model by Monte Carlo simulation (MCS). METHODS: According to erlotinib PPK model (150 mg po qd), 10 000 MCS were estimated for missed doses and remedial dosage regimens (6 h, 12 h, 18 h, and 24 h double doses) by NONMEM. The proportion of people outside the individual treatment window (ITW) and duration outside the ITW (>5%) under the missed and remedial regimens were calculated, and the rationality of the supplemental regimen in each scenario were analyzed. RESULTS: When missed taking erlotinib, the drug concentration continued to drop to the next medication time and affected the next day's concentration. The durations below the ITW were 25.1 h and 6.6 h, respectively. The proportion of people below ITW increased from 6.82% to 14.55%, and the duration time increased from 5.9 h to 23.6 h; the proportion of people above ITW increased from 5.99% to 10.74%, and the duration time increased from 3.7 h to 9.7 h. CONCLUSION: According to MCS results, patients should improve erlotinib medication compliance and avoid missed doses. In case of missed dose, remedial should be given as soon as possible, but it is not recommended to take remedial or double dosage near the next administration time to avoid increased adverse drug reactions.

Key words: erlotinib, medication adherence, population pharmacokinetics, Monte Carlo simulation

中图分类号:

R734.2

许高奇, 张轶雯, 郑小卫,刘宇佳,李莉,黄萍. 蒙特卡洛模拟厄洛替尼漏服及补服方案评价[J]. 中国临床药理学与治疗学, 2020, 25(5): 540-545.

XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping. Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.

参考文献

[1]Díaz-Serrano A, Gella P, Jiménez E, et al. Targeting EGFR in lung cancer: current standards and developments [J]. Drugs, 2018, 78(9): 893-911.
[2]肖博文, 姚敦武, 付滢舟, 等. 非小细胞肺癌患者厄洛替尼个体化给药研究进展[J]. 中南药学, 2018, 16(11): 58-62.
[3]余奇, 郭澄. 酪氨酸激酶抑制剂厄洛替尼的研究进展 [J]. 药学服务与研究, 2010, 10(6): 453-457.
[4]Petit-Jean E, Buclin T, Guidi M, et al. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature [J]. Therap Drug Mon, 2015, 37(1): 2-21.
[5]White-Koning M, Civade E, Geoerger B, et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children[J]. Clin Cancer Res, 2011, 17(14): 4862-4871.
[6]焦正, 丁俊杰, 赵晨妍. 建模和模拟技术在用药依从性研究中的应用 [J]. 药学服务与研究, 2014, 14(6): 418-420.
[7]许高奇, 朱立勤, 葛婷悦, 等. 儿童侵袭性念珠菌感染的米卡芬净给药方案的优化 [J]. 中国新药与临床杂志, 2016, 35(7): 482-486.
[8]Lu J , Eppler S , Wolf J , et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer [J]. Clin Pharmacol Thera, 2006, 80(2): 136-145.
[9]Yu EQ, Jiao Z, Wang CY, et al. Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations [J]. Epil Behav, 2019, 96: 132-140.
[10]Ni J, Zhang L. Evaluation of three small molecular drugs for targeted therapy to treat non-small cell lung cancer [J]. Chin Med J, 2016, 129(3): 332.

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	黄志伟, 李熠, 徐晓勇, 张蕾, 沈一峰, 李华芳. 五种群体药动学分析工具计算结果的比较[J]. 中国临床药理学与治疗学, 2023, 28(5): 525-535.
[3]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[4]	寇晨, 李兆娜, 张亚南, 高正平, 张拓慧. 应用蒙特卡洛模拟评价新生儿革兰阳性球菌晚发型败血症的药敏变迁[J]. 中国临床药理学与治疗学, 2021, 26(12): 1400-1406.
[5]	郭仙忠, 林荣芳, 林玮玮. 基于群体药动学模型的万古霉素个体化给药软件研制及应用[J]. 中国临床药理学与治疗学, 2021, 26(1): 30-39.
[6]	林忠, 谢群莉, 戴淑萍, 陈静, 林菲阳, 朱燕舞, 余国亮, 张远怀, 崔可. 中国成年患者利奈唑胺治疗群体药动学研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 992-999.
[7]	刘思敏，蔡俊，李慧馨，杨立，赵燕，张晋萍. 成人应用伏立康唑的群体药动学研究进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1015-1023.
[8]	马广立, 许羚, 陈锐, 陈渊成, 赵维, 刘东阳, 焦正, 李健, 季双敏, 李丽, 李良, 王玉珠, 杨进波, 王亚宁, 孙鹤, 胡蓓, 郑青山, 卢炜. 新药研发中群体药动学/药效学研究的一般考虑[J]. 中国临床药理学与治疗学, 2019, 24(11): 1201-1220.
[9]	戴映，张海娜，林观样，余旭奔. 伏立康唑群体药动学研究及其在给药方案设计中的应用进展[J]. 中国临床药理学与治疗学, 2018, 23(9): 1063-1067.
[10]	李静静，虞燕霞，唐莲，张金坤，余强，尚尔宁. 临床药学服务对幽门螺杆菌阳性消化性溃疡患者用药依从性及治疗效果的影响分析[J]. 中国临床药理学与治疗学, 2018, 23(2): 199-204.
[11]	吴永磊，王丹，张睢扬，王英，孙芹. 比较美罗培南传统延长和优化延长输注在脓毒症大鼠不同组织中的药代动力学/药效动力学[J]. 中国临床药理学与治疗学, 2017, 22(7): 767-774.
[12]	张弨, 袭辰辰, 戈梦佳. 基于群体药动学和药效学模型优化成年感染患者的哌拉西林/他唑巴坦给药方案[J]. 中国临床药理学与治疗学, 2015, 20(9): 1037-1041.
[13]	李国柱, 谢海棠, 陈佰锋, 王浩, 孙笑天. 成人用药依从性调查及影响因素分析[J]. 中国临床药理学与治疗学, 2015, 20(1): 47-50.
[14]	谌茜, 李敏, 马倬, 吴丹丹, 倪萍, 翟溯澜, 李萍, 邹美娟, 王雪融. FASN对Erlotinib耐药细胞株生长的影响及其机制[J]. 中国临床药理学与治疗学, 2014, 19(10): 1120-1125.
[15]	孙安修, 刘阳晨, 顾玲, 吕建锋, 范辉, 石爱平, 王琳. 阿司匹林用药依从性的干预研究[J]. 中国临床药理学与治疗学, 2009, 14(10): 1156-1159.

蒙特卡洛模拟厄洛替尼漏服及补服方案评价

Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价